Suchergebnisse - "Subbiah, Vivek"

PubPharm (33)

1

Lurbinectedin in patients with pretreated endometrial cancer : results from a phase 2 basket clinical trial and exploratory translational study

enthalten in: Investigational new drugs | 2023

von Kristeleit, R. | Leary, A. | Delord, J. | +15

2

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers : the phase 2 ROAR trial

enthalten in: Nature medicine | 2023

von Subbiah, V. | Kreitman, R. | Wainberg, Z. | +20

CommentIn: Nat Rev Clin Oncol. 2023 Jul;20(7):425. - PMID 37169890

3

A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors

enthalten in: Cancer | 2023

von Janku, F. | Javle, M. | Sen, S. | +14

4

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer : Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Drilon, A. | Subbiah, V. | Gautschi, O. | +15

CommentIn: J Clin Oncol. 2023 Jan 10;41(2):410-412. - PMID 36122320

5

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001) : a phase 1/2, open-label, basket trial

enthalten in: The Lancet. Oncology | 2022

von Subbiah, V. | Wolf, J. | Konda, B. | +12

CommentIn: Lancet Oncol. 2022 Oct;23(10):1235-1237. - PMID 36108663

6

Lurbinectedin in patients with pretreated neuroendocrine tumours : Results from a phase II basket study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Longo-Muñoz, F. | Castellano, D. | Alexandre, J. | +11

7

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

enthalten in: Scientific reports | 2022

von Mendoza, T. | Hong, D. | Peterson, C. | +20

8

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

enthalten in: Nature medicine | 2022

von Subbiah, V. | Cassier, P. | Siena, S. | +16

CommentIn: Nat Rev Clin Oncol. 2022 Oct;19(10):615. - PMID 35999290

9

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma : Results of a Basket Phase II Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Subbiah, V. | Braña, I. | Longhi, A. | +14

10

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial

enthalten in: The oncologist | 2022

von Wirth, L. | Robinson, B. | Boni, V. | +8

ErratumIn: Oncologist. 2022 Dec 9;27(12):e982. - PMID 36269631